Wishing you a happy and healthy Thanksgiving holiday, from our family to yours. #Pelthos

We are wishing you and yours a happy holiday season! #Pelthos

Happy New Year! Wishing you a safe and prosperous new year. #Pelthos

Today we completed our merger with Channel Therapeutics and a $50.1 million private placement to launch #ZELSUVMI, the first and only at-home treatment for #molluscum. bit.ly/3IaezzM

We are proud to share that Pelthos officially began trading on the NYSE 🏛 American exchange yesterday under the ticker symbol $PTHS. Thank you to everyone who helped make this day possible. #NYSEAmerican #Listed #MilestoneMoment #PublicCompany

We are pleased to announce Sai Rangarao has been promoted to Chief Commercial Officer at $PTHS. Sai will lead our commercialization efforts for #ZELSUVMI.

Today we are proud to launch #ZELSUVMI. The product is now available by prescription through retail pharmacies, ASPN pharmacy services and for at-home delivery through mail-order pharmacies. Learn more: bit.ly/4kz8uu5

❗Pelthos Therapeutics announced it has launched berdazimer topical gel, 10.3% (Zelsuvmi), a first-in-class, nitric oxide-releasing gel approved for at-home application in adults and children aged 1 year and older. hubs.li/Q03wJ8_r0

Pelthos Therapeutics has launched berdazimer (Zelsuvmi) topical gel, 10.3%, for the treatment of molluscum contagiosum in adults and pediatric patients aged 1 year and older. Full details: hubs.li/Q03wLz2s0

JUST IN: Pelthos Therapeutics is officially launching berdazimer topical gel, 10.3% (Zelsuvmi) for the treatment of #molluscum contagiosum in adults and pediatric patients one year of age and older. jdnppa.com/berdazimer-top…

Berdazimer topical gel, 10.3% (ZELSUVMI) is the first FDA-approved at-home treatment for #MolluscumContagiosum, offering an option for patients aged 1+ years. View more: hcplive.com/view/berdazime…

Our team will be onsite at #DERM2025 this week. If you are attending, swing by Booth 308 to learn about #ZELSUVMI (berdazimer) 10.3% topical gel, now available by prescription through retail pharmacies, ASPN pharmacy services, and at-home delivery. Visit zelsuvmi.com.

Today we announced financial results for our legacy operations for the period ended June 30, 2025. We also highlighted our company’s progress since completing our merger with Channel Therapeutics and closing a $50.1 million private placement financing. bit.ly/4oE0wDm

Pelthos is proud to sponsor the LEADderm conference, which brings together industry leaders to help shape the future of dermatology. We are excited to support this important forum for collaboration, community building, and discovery. #Dermatology #DermatologyInnovation #ZELSUVMI

This Wednesday, our CEO Scott Plesha and CFO Frank Knuettel will present at the 2025 Wells Fargo Healthcare Conference in Boston at 1:30pm ET. View the press release here: bit.ly/3UTIzDl

Our senior management team will discuss Pelthos' corporate strategy and outlook at several investor conferences this month. Read more: bit.ly/3I4mEXa

The Pelthos team will be on-site at the American Academy of Pediatrics 2025 National Conference & Exhibition, the premier gathering for pediatric healthcare professionals. If you will be in Denver, please stop by Booth #309.

Pelthos launches #MomsAgainstMolluscum movement to unite mothers, parents, and other caregivers navigating #molluscum contagiosum. Visit momsagainstmolluscum.com to learn more. bit.ly/43cNDHc

Today we announced the acquisition of Xepi® (ozenoxacin) Cream, 1%, an FDA-approved treatment for impetigo and an $18M private convertible notes financing. Our product portfolio targeting skin infections is growing. bit.ly/3JLvhqp #Xepi

Pelthos will report Q3 2025 financial results before the opening of the U.S. financial markets on November 13 followed by a conference call at 8:00am ET. Register: bit.ly/4pmHfGj